Clinical trial
Study of BMS-562086 in the Treatment of Outpatients With Major Depressive…
NCT00135421 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00135421 |
|---|---|
| Title | Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Major Depressive Disorder |
| Intervention type | Drug |
| Interventions | Pexacerfont, Escitalopram, Placebo |
| Enrollment | 271 |
| Start date | Nov 1, 2005 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Aug 26, 2005 |
| Last update posted | Mar 2, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: